A longitudinal study of the peripheral and central auditory pathways in individuals with acute lymphoid leukemia.
Auditory evoked potentials
Auditory perception
Hearing
Leukemia-lymphoblastic precursor cell lymphoma
Pharmacological treatment
Journal
Clinics (Sao Paulo, Brazil)
ISSN: 1980-5322
Titre abrégé: Clinics (Sao Paulo)
Pays: United States
ID NLM: 101244734
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
11
2022
revised:
10
05
2023
accepted:
01
06
2023
medline:
29
6
2023
pubmed:
26
6
2023
entrez:
25
6
2023
Statut:
epublish
Résumé
To characterize the peripheral and central auditory pathways in individuals with Acute Lymphoid Leukemia (ALL) and compare assessment results before and during chemotherapy. The study included 17 subjects with ALL, divided into two age groups: 3 to 6 (11 individuals) and 7 to 16 years old (6 individuals). Each subject was evaluated twice (before and 3 to 6 months after chemotherapy treatment) with the following procedures: medical history survey, otoscopy, Pure-Tone Threshold (PTA) and speech audiometry, acoustic immittance measures, Brainstem Auditory Evoked Potentials (BAEP) and Long-Latency Auditory Evoked Potentials (LLAEP). PTA was normal. Tympanometry was abnormal in the second assessment in 2 individuals aged 3 to 6 years. One subject in each age group had absent ipsilateral acoustic reflexes. In high-frequency audiometry, 1 individual had abnormal results. BAEP was abnormal in 5 (first assessment) and 7 individuals (second assessment) aged 3 to 6 years and 2 (first assessment) and 1 individual (second assessment) aged 7 to 16 years. As for LLAEP, P1 latency was increased in 5 (first assessment) and 7 individuals (second assessment) aged 3 to 6 years. No hearing loss was identified in the behavioral audiological assessment. BAEP was more affected in the 3-to-6-year-old group, with greater impairment in the lower brainstem in the first and second assessments. In LLAEP, P1 was the most impaired component in children aged 3 to 6 years, and P2 and N2 were so for those 7 to 16 years old, especially in the second assessment.
Identifiants
pubmed: 37356412
pii: S1807-5932(23)00070-4
doi: 10.1016/j.clinsp.2023.100234
pmc: PMC10310478
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100234Informations de copyright
Copyright © 2023 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflicts of interest.
Références
Braz J Otorhinolaryngol. 2006 Nov-Dec;72(6):836-44
pubmed: 17308839
Eur J Pediatr. 1990 Dec;150(2):127-31
pubmed: 2279509
BMC Womens Health. 2017 Dec 11;17(1):129
pubmed: 29228931
J Pediatr Nurs. 2003 Apr;18(2):103-12
pubmed: 12720207
Arq Neuropsiquiatr. 2020 Feb;78(2):63-69
pubmed: 32022120
Braz J Otorhinolaryngol. 2009 Mar-Apr;75(2):231-6
pubmed: 19575109
Braz J Otorhinolaryngol. 2007 Sep-Oct;73(5):608-14
pubmed: 18094801
J Pediatr (Rio J). 2008 Aug;84(4 Suppl):S52-7
pubmed: 18830516
Br J Cancer. 1994 Nov;70(5):969-72
pubmed: 7947106
Pro Fono. 2010 Jul-Sep;22(3):281-6
pubmed: 21103719
Przegl Lek. 2006;63(11):1205-9
pubmed: 17348417
Arch Otolaryngol. 1970 Oct;92(4):311-24
pubmed: 5455571
Bol Med Hosp Infant Mex. 2017 Jul - Aug;74(4):243-264
pubmed: 29382514
Braz J Otorhinolaryngol. 2015 Nov-Dec;81(6):589-97
pubmed: 26480907
Otolaryngol Clin North Am. 1991 Apr;24(2):349-70
pubmed: 1857616
J Clin Med. 2021 Apr 29;10(9):
pubmed: 33946897